JRCT ID: jRCT1080224630
Registered date:09/04/2019
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 04/02/2019 |
Target sample size | 230 |
Countries of recruitment | Japan,Asia except Japan,North America,South America,Europe,Oceania,Africa |
Study type | Observational |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : - Therapeutic category code : 634 Human blood preparations Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 12age old |
---|---|
Age maximum | Not applicable |
Gender | Male |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | Novo Nordisk Pharma Ltd. |
---|---|
Secondary Sponsor | - |
Source(s) of Monetary Support | Novo Nordisk Pharma Ltd. |
Secondary ID(s) | NCT03741881,JapicCTI-194702 |
Contact
Public contact | |
Name | |
Address | Meiji Yasuda Seimei Bldg., 2-1-1, Marunouchi, Chiyoda-ku, Tokyo |
Telephone | |
Affiliation | Novo Nordisk Pharma Ltd. |
Scientific contact | |
Name | |
Address | Meiji Yasuda Seimei Bldg., 2-1-1, Marunouchi, Chiyoda-ku, Tokyo |
Telephone | |
Affiliation | Novo Nordisk Pharma Ltd. |